CompletedNCT01018992

Evaluation of GSK561679 in Women With PTSD

Researchers compared GSK561679 and placebo to find out how the approaches affected post-traumatic stress symptoms in women with PTSD.

Medication studyAges 21–65United States

The study in practice

Understand this study

Researchers compared GSK561679 and placebo to find out how the approaches affected post-traumatic stress symptoms in women with PTSD.

Listed age limits: 21 years to 65 years.

Listed locations: San Francisco, United States · Atlanta, United States and 2 more locationsSee all locations and recruitment
Activities: Medication described in the protocol · Placebo comparator
Compensation: Payment and expense reimbursement have not been verified.

Study clarity

Study start dateDecember 2009

Recruitment status: Completed
Enrollment listed in the registry: 267
Sponsor: Emory University
Sponsor type: University
Study type: Drug
Intervention type: Medication / drug
Study phase: Phase 2
Locations: United States
Age range: From 21 Years to 65 Years
Official registry ID: NCT01018992
Official title: Show the full official title
Evaluation of the Efficacy of the CRF1 Antagonist GSK561679 in Women With Post-traumatic Stress Disorder

Completed

San Francisco · Atlanta · New York

1 more locations

FAQ

What did researchers investigate?

Researchers compared GSK561679 and placebo to find out how the approaches affected post-traumatic stress symptoms in women with PTSD.

Who is behind this study?

The study sponsor is Emory University, a university.

Did this study involve medication?

Yes. The study involved medication, including GSK561679 and Placebo.

Who was this study for?

Listed age limits: 21 years to 65 years.

Explore other studies

Answer a few simple questions to explore HopeStage studies by condition, country, and situation.